We were delighted to speak with Prof. Christopher Butler (University of Oxford, Oxford, UK) about antiviral therapies for influenza and, in particular, the findings from the ALIC4E trial.
Questions
1. What are the current recommendations for the use of antiviral therapy for the treatment of influenza? (0:07)
2. Why is oseltamivir not more widely used in the treatment of influenza? (1:00)
3. Could you tell us a little about the ALIC4E clinical trial design and its findings in terms of who is most likely to benefit? (2:32)
4. What other studies are ongoing/are planned? (5:18)
Speaker disclosure: Christopher Butler is the principal investigator of the ALIC4E clinical trial.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020.
